# Dynamic Cell Therapies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dynamic-cell-therapies

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.dynamiccelltherapies.com
- Total disclosed funding: $1M
- Latest round: Seed (Jul 11, 2024)
- Investors on record: 1

## About

Based in Massachusetts, US, and founded in 2020 by Chief Executive Officer Fred Mermelstein and Chief Legal Officer Julia A. Novina, Dynamic Cell Therapies, Inc. operates as a biopharmaceutical company developing innovative CAR T-cell therapies to enhance the treatment of both liquid and solid tumors. In July 2024, Dynamic Cell Therapies, Inc. raised USD 1 million in venture funding from Myeloma Investment Fund. 

Dynamic Cell Therapies, Inc. developed a technology that allows for the dynamic control of engineered T cells by separating tumor targeting from CAR T cell activation. It is programmed to recognize an inert small molecule that is linked to a tumor-specific antibody by dosing this small molecule-antibody conjugate, physicians can modulate CAR T cell activity to reduces life-threatening side effects and improve the immune response against cancer cells. In addition, the firm’s method also permits the use of various antibodies targeting different tumor antigens, thus optimizing on-target tumor efficacy and reducing off-target toxicities.

## Funding rounds

- Seed, Jul 11, 2024, $1M — Myeloma Investment Fund

## Investors

- Myeloma Investment Fund (https://capitalatlas.ai/funds/myeloma-investment-fund) — Seed